Shalby Limited – Investor Presentation Summary

Key Operational Highlights

  • In-Patient count reached 23,895 in Q1 FY27, up 6.2% YoY from 22,499 in Q1 FY26
  • Out Patient count was 128,139 in Q1 FY27, down 4.5% YoY from 134,122
  • Surgeries Count increased to 9,326 in Q1 FY27, up 3.5% YoY from 9,013
  • ARPOB stood at ₹44,711 in Q1 FY27, down 2.1% YoY from ₹45,673
  • Operational Beds were 1,365 in Q1 FY27, down 3.5% YoY from 1,415
  • Occupied Beds reached 701 in Q1 FY27, up 9.8% YoY from 639
  • Occupancy Rate improved to 51% in Q1 FY27, up 624 bps from 45% in Q1 FY26
  • ALOS (without Daycare) was 3.69 days in Q1 FY27, up 4.5% YoY from 3.53 days

Key drivers of operational performance: Improved occupancy rates, growth in surgical procedures, and expansion of hospital network.

Segment-wise Performance

  • Shalby Hospitals, Pharma & Franchise: Revenue ₹2,652.2 million (78.32% of total), EBITDA ₹450.5 million
  • Shalby International (PK Healthcare, Delhi-NCR): Revenue ₹262.3 million (7.75% of total), EBITDA ₹39.2 million
  • Shalby MedTech (Implant Business): Revenue ₹471.7 million (13.92% of total), EBITDA ₹1.6 million
  • Others: Revenue ₹0.2 million (0.01% of total), EBITDA (₹1.3) million

Explanation of significant changes in segment performance: Hospital business remains the dominant revenue contributor while implant business shows revenue growth but minimal profitability.

Financial Highlights

Revenue: ₹3,386 million

EBITDA: ₹490 million

PAT: ₹105 million

EPS: Not Specified

Margins: EBITDA Margin 14.5%, PBT Margin 5.8%, PAT Margin 3.1%

YoY/QoQ comparison: Revenue up 11.6% YoY and 14.6% QoQ; PAT up 36.7% YoY but down 43.1% QoQ

Drivers of financial performance: Revenue growth across business segments, improved operational efficiency

Comparison to market estimates: Not Specified

Key Risks: Not explicitly disclosed in presentation

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not Specified

Regional Breakdown: Not Specified

Balance Sheet Snapshot

Net Debt/Equity: Debt/Equity ratio 0.46x

Reserves: Not Specified

Current Assets/Liabilities: Not Specified

Working Capital/Leverage Metrics: Not Specified

Financial Health Insights: Gross Borrowings ₹5,509 million, Cash & Cash Equivalents ₹873 million, Net Debt (₹4,636) million

Capex & Cash Flow Health

Capital Expenditure: Not Specified

Free Cash Flow: Not Specified

Operating Cash Flow: Not Specified

Net Debt Movement: Not Specified

Investment Rationale: Focus on hospital expansion and implant business growth

Strategic & R&D Initiatives

Investments in Innovation: Implant manufacturing facility in California, USA; distribution facility in India and South-East Asian countries

Expected impact on growth: Global expansion of implant business to new markets

Strategic Rationale: Maintaining global leadership in joint replacements while diversifying into Cardiac Science, Oncology, Neuro-science, Critical Care, General Medicine and Transplants

Industry Trends & Business Environment

Macro/Industry Trends: Not Specified

Impact on Company: Not Specified

Management Commentary & Growth Outlook

Strategic Outlook: Aspiration of growing multifold while preserving core values of "Passion, Compassion and Innovation"

FY Guidance: Not Specified

Market Share Targets: Not Specified

Risks and Opportunities: Not Specified